RetroSense poised to take vision restoration gene therapy into clinic
This article was originally published in Scrip
Executive Summary
RetroSense says it is on track with plans to move its lead candidate RST-001, a gene therapy for vision restoration in retinal degenerative conditions, into the clinic next year. The company said it is currently raising money to fund the Phase I study.